Alterity Therapeutics has secured official FDA confirmation that a single pivotal Phase 3 trial, backed by prior Phase 2 data, can support approval of ATH434 for Multiple System Atrophy. Trial initiation remains on track for late 2026.
- FDA endorses single pivotal Phase 3 trial plus confirmatory evidence
- Phase 3 design includes 200 patients, 12-month treatment, functional endpoints
- ATH434 targets iron accumulation and α-synuclein pathology in MSA
- Positive Phase 2 data underpin confirmatory evidence for approval
- Trial activities expected to start by year-end 2026
FDA Endorses Efficient Pathway to Approval for ATH434
Alterity Therapeutics (ASX:ATH, NASDAQ: ATHE) has received official minutes from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, confirming a clear and streamlined regulatory path for its lead candidate ATH434 in Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, supplemented by confirmatory data from the company’s Phase 2 program, could suffice to support a New Drug Application (NDA) for this rare neurodegenerative disease.
Chief Executive Officer David Stamler described the FDA’s acceptance of a single pivotal study as a significant endorsement of the Phase 3 program design, which includes approximately 200 patients being randomized to receive ATH434 or placebo twice daily over 12 months. The primary endpoint will be the 11-item Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, focusing on functional activities of daily living impacted by MSA.
Trial Design and Endpoints Confirmed
The FDA’s detailed feedback validated the study population, dosing regimen, and key efficacy measures. Secondary endpoints include assessments of swallowing difficulties, orthostatic hypotension symptoms, and clinical global impression of severity, providing a comprehensive evaluation of ATH434’s potential benefits. The company is finalizing the Phase 3 protocol, aiming to commence trial activities by the end of 2026.
Alterity plans to offer an open-label extension for Phase 3 participants, which will not only extend patient access to the drug but also bolster the safety database, a critical component for regulatory review. The FDA indicated that the anticipated safety data volume at trial completion appears adequate.
ATH434’s Mechanism and Clinical Promise
ATH434 is an oral iron chaperone designed to restore iron balance in the brain and inhibit aggregation of α-synuclein, a pathological hallmark of MSA and related Parkinsonian disorders. Positive Phase 2 results demonstrated meaningful slowing of disease progression, target engagement through biomarker changes, and a favourable safety profile. These findings underpin the FDA’s openness to a single pivotal trial supported by this confirmatory evidence.
The drug has already secured Fast Track and Orphan Drug designations from the FDA, recognising the urgent need for disease-modifying therapies in MSA, which currently lacks approved treatments to slow its rapid progression.
Implications for Alterity’s Development Timeline
The FDA’s official minutes solidify the clinical development roadmap for ATH434, reinforcing the company’s timeline to initiate Phase 3 by year-end 2026. This regulatory clarity reduces uncertainty around trial design and approval requirements, a critical step for investors and stakeholders tracking Alterity’s progress in a challenging therapeutic area.
With Phase 2 data already showing promising efficacy signals, the upcoming Phase 3 trial will be pivotal in determining ATH434’s potential as a first-in-class treatment for MSA. The open-label extension also suggests a strategy to accumulate robust long-term safety data, which could support broader regulatory submissions.
Bottom Line?
Alterity’s FDA confirmation on a single pivotal trial sharpens the path to potential approval, setting the stage for a critical Phase 3 readout starting late 2026.
Questions in the middle?
- How will ATH434’s Phase 3 results compare to the promising Phase 2 efficacy signals?
- What impact will the open-label extension have on long-term safety and efficacy data?
- Could ATH434’s mechanism offer benefits beyond MSA, such as in Parkinson’s disease?